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The antitumoral profile of the microtubule disrupter N-(4-iodophenyl)-N0-(2-chloroethyl)urea (ICEU) was characterised in vitro and in
vivo using the CT-26 colon carcinoma cell line, on the basis of the drug uptake by the cells, the modifications of cell cycle, and
b-tubulin and lipid membrane profiles. N-(4-iodophenyl)-N0-(2-chloroethyl)urea exhibited a rapid and dose-dependent uptake by
CT-26 cells suggesting its passive diffusion through the membranes. Intraperitoneally injected ICEU biodistributed into the grafted
CT-26 tumour, resulting thus in a significant tumour growth inhibition (TGI). N-(4-iodophenyl)-N0-(2-chloroethyl)urea was also
observed to accumulate within colon tissue. Tumour growth inhibition was associated with a slight increase in the number of G2
tetraploid tumour cells in vivo, whereas G2 blockage was more obvious in vitro. The phenotype of b-tubulin alkylation that was clearly
demonstrated in vitro was undetectable in vivo. Nuclear magnetic resonance analysis showed that cells blocked in G2 phase
underwent apoptosis, as confirmed by an increase in the methylene group resonance of mobile lipids, parallel to sub-G1 accumulation
of the cells. In vivo, a decrease of the signals of both the phospholipid precursors and the products of membrane degradation
occurred concomitantly with TGI. This multi-analysis established, at least partly, the ICEU activity profile, in vitro and in vivo, providing
additional data in favour of ICEU as a tubulin-interacting drug accumulating within the intestinal tract. This may provide a starting point
for researches for future efficacious tubulin-interacting drugs for the treatment of colorectal cancers.
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The major role of microtubules in cell division makes tubulin one
of the most prominent and studied target for the development of
new antitumour drugs, especially for solid tumours. The taxanes
and the vinca alkaloids are effective in the treatment of many
cancers in humans, but their therapeutic efficacy is hampered by
acquired or intrinsic drug resistance of the tumour cells (Cabral,
2001; Drukman and Kavallaris, 2002; Wilson and Jordan, 2004). To
circumvent these problems, extensive research programmes have
been focusing on finding selective therapies that are less prone to
induce resistant phenotypes in tumour cells. In the past decade,
N-aryl-N0-(2-chloroethyl)ureas (CEUs) have exhibited promising
antitumoral activity through alkylation of b-tubulin near the
colchicine-binding site. N-aryl-N0-(2-chloroethyl)ureas are mole-
cular hybrids obtained from the biofunctional moiety of aromatic
nitrogen mustards and the non-nitrosated pharmacophore
of aliphatic nitrosoureas (Gaudreault et al, 1988; Lacroix et al,
1988; Bechard et al, 1994; Mounetou et al, 2001, 2003). N-
(4-iodophenyl)-N0-(2-chloroethyl)-urea (ICEU) was selected for
study on the basis of a low inhibition concentration (IC50)o n
several tumour cell lines resistant to numerous other chemo-
therapeutic agents. In vitro studies have shown that ICEU
cytotoxicity is linked to cytoskeleton disruption following micro-
tubule depolymerisation, resulting from b-tubulin alkylation of the
glutamic acid residue at position 198 (Petitclerc et al, 2004;
Bouchon et al, 2005). Finally, ICEU has displayed significant
antitumoral activity in the murine CT-26 colon carcinoma model,
antitumoral activity that is, at least partly, associated with an
antiangiogenic effect (Miot-Noirault et al, 2004; Petitclerc et al,
2004). Furthermore, ICEU can be readily radiolabelled with either
iodine-123 (
123I) for scintigraphic analysis or iodine-131 (
131I) for
radiotherapy applications.
The purpose of the study was to characterise the antitumoral
profile of ICEU using four main criteria. Using the CT-26 murine
colon carcinoma cell line, we first studied ICEU uptake and its
effects on the cell cycle, b-tubulin and membrane lipid profiles in
vitro; afterwards, we tried to correlate in vitro findings with those
on CT-26 tumours grafted to mice. The data showed that
[
125I]ICEU was rapidly absorbed and distributed to the CT-26
colon carcinoma tissue in vivo and being taken up by the cells
according to a passive diffusion mechanism. N-(4-iodophenyl)-
N0-(2-chloroethyl)urea induced inhibition of cell growth
through arrest of cell division in G2 phase in either CT-26 cells
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sor in CT-26-derived tumours. Sodium dodecyl sulphate (SDS)-
PAGE analysis of ICEU-treated cells and tumours showed clearly
the phenotype of b-tubulin alkylation in vitro, but not in vivo.
Furthermore, proton high-resolution magic angle spinning nuclear
magnetic resonance (
1H-HRMAS NMR) analysis showed evidence
of changes in both the mobile lipids and the phospholipids, those
changes being characteristic of the apoptosis taking place in vitro
and the reduction of cell membrane turnover and the cell
proliferation occurring in vivo.
This multi-analysis brings additional data that contribute to a
better understanding of the antitumoral action of ICEU.
MATERIALS AND METHODS
CT-26 murine carcinoma cell line
The CT-26 cell line was kindly provided by Dr IJ Fidler (MD
Anderson Cancer Center, Houston, TX, USA).
For in vitro experiments, cells were grown as monolayer cultures
in minimum essential medium with Earle’s salts (MEM
s, Gibco-
BRL, Cergy Pontoise, France) supplemented with 10% foetal calf
serum (Sigma-Aldrich, St Quentin, Fallavier, France), 1% solution
of vitamins (Gibco-BRL), 1% sodium pyruvate (Gibco-BRL), 1%
nonessential amino acids (Gibco-BRL) and 0.04% gentamycin base
(Gibco-BRL) at 371Ci n5 %C O 2 and at 100% humidity.
For in vivo experiments, CT-26 tumour grafts were established
in 67 male 6-week-old Balb/c mice (Charles River, L’Arbresle,
France) by subcutaneous (s.c.) injection of 2 10
5 CT-26 cells in
the right flank at day 0. Animals were randomly assigned to either
a biodistribution study (n¼42) or an antitumoral efficacy study
(n¼25). Tumour volumes (in mm
3) were calculated from the
measurement of two perpendicular diameters using a caliper,
according to the formula: L S
2/2, where L and S are the largest
and smallest diameters in mm, respectively.
All animal studies were performed under the authorisation of
the French Veterinary Services Directorate (authorisation no. C63-
113-10) and conducted under the supervision of authorised
investigators in accordance to the institution’s recommendations
for the use of laboratory animals and with UKCCCR guidelines
(Workman et al, 1998).
In vitro and in vivo drug treatment
N-(4-iodophenyl)-N0-(2-chloroethyl)urea was synthesised (Figure 1)
as previously described (Mounetou et al, 2001).
For in vitro experiments, both unlabelled ICEU and [
125I]ICEU
(specific activity: 1.5GBqmmol
 1) were dissolved in dimethyl-
sulphoxide (DMSO). Two million (2 10
6) cells were plated in 10-
mm Petri dishes 24h prior to the addition of escalating
concentrations of the drug for different period of time. After
incubation, the cells were harvested by scraping. The cell
suspension containing both floating and adherent cells was spun
twice (400g, 8min, 41C) in PBS. Dry pellets were then stored (i) in
liquid nitrogen prior to cell cycle and western blotting analyses or
(ii) at  801C until
1H-HRMAS NMR analysis.
For the cellular uptake study, after incubation with [
125I]ICEU,
the medium was quickly removed and the cells were washed with
cold PBS, scraped and counted for radioactivity (Minaxi g 5530
gamma counter, Packard Rungis, Rungis, France). Drug uptake
was expressed in pmoles of [
125I]ICEU per mg of proteins, with the
protein content being determined by the Bradford’s method using
Coomassie Blue G250 solution (Pierce, Oud-Bejerland, The
Netherlands) (Bradford, 1976; Sapan et al, 1999).
For in vivo experiments, both unlabelled ICEU and [
125I]ICEU
(specific activity¼734.5MBqmmol
 1) were dissolved in a mixture
of Labrafils
s M1944 Cs (Gattefosse ´, Gennevilliers, France),
dimethylacetamide (Sigma-Aldrich, France), and Tween 80
s
(Sigma-Aldrich, France) (89/9/1%, vv
 1) as previously described
(Miot-Noirault et al, 2004). For biodistribution studies, the
previously determined maximum-tolerated dose (MTD) of
13mgkg
 1 (Miot-Noirault et al, 2004) of [
125I]ICEU (activity per
mouse: 74KBq) were administered intraperitoneally (i.p.) to the
animals when tumours had reached approximately 5mm in
diameter (day 10).
For the antitumoral efficacy study, we used the previously
published ICEU ‘infraclinical protocol’, since it was successful in
inducing antitumour effects similar to those observed when using
5-fluorouracil (5-Fu) as positive control (Miot-Noirault et al, 2004;
Petitclerc et al, 2004). N-(4-iodophenyl)-N0-(2-chloroethyl)urea
was therefore injected i.p at the MTD of 13mgkg
 1 at days 1, 5 and
9( n¼13 animals), while mice in the control group (n¼12) were
sham treated. During this antitumoral efficacy study, the toxic
effects of ICEU were assessed by the evaluation of the ‘clinical
state’ of each animal where both the mortality and ‘poor health’
symptoms such as weight loss, lethargy, rough coat, closed eyes
and diarrhoea were assessed.
Our objective was also to compare ICEU-treated and control
tumour samples for cell cycle, b tubulin and lipid profiling, when a
high growth inhibition was observed. Two tumours from control
and treated groups were excised at days 9, 11, 15 and 18, on the
basis on our previous results that have demonstrated a high
inhibition level of the tumour growth at the stages day 9 and day
11 and a growth relapse from day 15 (Miot-Noirault et al, 2004).
The tumours were carefully divided in three equivalent aliquots
that were immediately and respectively disaggregated for cell cycle
analysis, frozen in liquid nitrogen, or stored at 801C until western
blotting or analysed by
1H HRMAS NMR spectroscopy.
Tissue distribution of [
125I]ICEU in CT-26-bearing mice
(n¼42)
At different time points after administration, the animals (n¼30; 3
animals per time point) were killed by CO2 inhalation, and then
immediately frozen in liquid nitrogen. The frozen animals were
cryosectioned into 40mm slices, and the radioactivity content of
the samples was assessed using quantitative whole body auto-
radiography (WBA) as previously described (Labarre et al, 1999).
Since WBA evaluation of colon radioactivity included the colon
mucosa and its contents, the radioactivity of the colon alone was
assessed from washed colon tissue aliquots excised from additional
CT-26-bearing mice (n¼12) killed at the same time points, using a
radioactivity counter (Minaxi g 5530, Packard, Rungis, France).
Uptake values were corrected for radioactive decay and expressed
as percentage of the injected dose per gram of tissues (% IDg
 1).
Flow cytometry DNA analysis
CT-26 tumour samples were mechanically disaggregated in PBS
solution by fine mincing with 26G needles and filtering through a
200mm nylon filter. The suspensions of cells were spun (400g,
8min, 41C), and the dry pellets obtained were stored in liquid
nitrogen. After thawing, the cell pellets and the tumour cell extracts
were resuspended in 500ml of ribonuclease A (1mgml
 1) (Sigma-
Aldrich, France) and 500ml of propidium iodide (1mgml
 1)
(Sigma-Aldrich, France) was added. After 30min at 41C in the
dark, the cell cycle was analysed using a flow cytometer (Coulter
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Figure 1 Chemical structure of N-(4-iodophenyl)-N0-(2-chloroethyl)
urea (ICEU).
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sEpics XL, Coulter, Hialeah, FL, USA) at wavelengths of 488 and
620nm, respectively.
b-Tubulin western blot analysis
For cell extracts, pellets were directly resuspended in Laemmli
buffer 1  as previously described (Legault et al, 2000). For
tumour cell extracts, samples were crushed and homogenised in
one volume of 10mM Tris-HCl buffer at pH 7.5 containing 0.25 M
sucrose and 10mM ethylenediaminetetraacetic acid, and 4 volumes
of the solubilisation buffer containing 8.4 M urea, 2.4 M thiourea,
50mM dithiothreitol and 5% 3-[(3-cholamidopropyl)dimethyl-
ammonio]-1-propanesulphonic acid (CHAPS) with a cocktail of
protease inhibitors. Extraction was carried out for 30min at room
temperature by vigorous shaking of the mixture and was followed
by ultracentrifugation at 100000g for 30min. The supernatants
were recovered and the protein content was determined by the
Bradford’s method as described above.
Sodium dodecyl sulphate-PAGE electrophoresis was performed
on a 10% acrylamide gel and the proteins were transferred
onto nitrocellulose membranes (Immobilon NC, Millipore,
St-Quentin-en Yvelines, France). Membranes were incubated with
an anti-b-tubulin anti-mouse antibody (Anti TUB2.1, Sigma,
St-Quentin-Fallavier, France). An additional incubation was
carried out with an HRP-labelled anti-mouse antibody (Dako,
Trappes, France) to reveal b-tubulin by chemoluminescence.
For cells treated with [
125I]ICEU, protein extracts were
processed as described above and autoradiographic analysis was
performed by exposing the dried gels to films.
The
1H-HRMAS NMR spectroscopy and data analysis
Proton high-resolution magic angle spinning nuclear magnetic
resonance spectroscopy was used to investigate the lipid profile of
both CT-26 cells and tumours after ICEU treatment.
This technique consists of spinning the sample at a rate
o10kHz around an axis tilted at 54.71 (magic angle) from the
magnet axis. The combination of a high-field magnet with the
HRMAS accessory allowed us to obtain high-resolution spectra of
small amounts (0.5–1mg) of biological materials. Analyses were
performed on a small-bore Bruker DRX 500 magnet (Bruker,
Karlsruhe, Germany) equipped with an HRMAS accessory. CT-26
cell preparations (8 10
6 cells in saline deuterium 9/1000 solution)
or intact CT-26 tumour material were set into 4-mm-diameter, 80-
ml Zirconia rotor tubes. One-dimensional (1D)
1H NMR spectra
were acquired at the magic angle at 293K with a rotor spin of
4KHz using 901 pulses preceded by 2s presaturation for water
signal suppression, giving a total measurement time of 48min for
1024 scans. For tumour sample analysis, 1D NMR spectra were
completed by two-dimensional homonuclear correlated spectra
(2D COSY) recorded by acquisition of 16 transients per increment
for 512 increments collected into 1K data points. A spectral width
of 5kHz was used in both dimensions. The time-domain data were
zero-filled and multiplied with a sine window function in both
dimensions before Fourier transformation. For data analysis, each
spectrum was phased and baseline-corrected using XWIN-NMR
version 2.6 (Bruker software). The resonances were assigned based
on the known chemical shifts of the major structural groups and
metabolites using published data (Bezabeh et al, 2001; Sitter et al,
2002; Brisdelli et al, 2003) and commercially available pure
metabolite reference spectra. The relative content of metabolites
was estimated by peak area integration using PeakFit software
(version 4, SPSS Science, Chicago, IL, USA). The intensity of
the contribution of b- and d-methylene protons of lysine (lys) to
the signal at 1.71ppm remained invariant during cell and
tumour sample manipulation, hence, the deconvolution area of
the lys signals was used as a reference as described previously
(Brisdelli et al, 2003). To compare the metabolic profiles between
experimental groups, metabolic ratios were calculated by dividing
the integrated area under the curve of each relevant peak by the
integrated area under the curve of the reference peak.
Tumour and cell sample stability inside the rotor was assessed
over several hours by a series of analyses. During the 48-min
overall acquisition period, no significant changes in NMR signals
of biological material were observed.
Each experiment was performed in triplicate.
Statistics
Data on tumour volumes and data from NMR analyses were
compared between control and treated groups using the Student’s
t-test for independent means. Two-sided P-values less than 0.05
was considered significant.
RESULTS
N-(4-iodophenyl)-N0-(2-chloroethyl)urea induced growth
inhibition of CT-26 cells grafted to mice
In the antitumour efficacy experiments, mice received three
intraperitoneal (i.p.) injections of ICEU (13mgkg
 1) at 4-day
intervals, starting on day 1 after cell inoculation (Figure 2). Mean
tumour volume was significantly lowered in the ICEU-treated
group than in the control group at day 9 (33.577.8 vs
83.477.4mm
3), day 11 (61.3712.1 vs 249.2742.7mm
3) and day
15 (283.5768.1 vs 594.8799.4mm
3), corresponding to a tumour
growth inhibition of 59.8, 75.4 and 52.3% respectively. From the
stage day 15, the ICEU-treated tumours were observed to relapse,
with no significant differences between control and treated groups
being observed at day 18. During the treatment of mice with ICEU
using the ‘infraclinical protocol’, that is, ICEU given at the MTD of
13mkkg
 1injection
 1 at days 1, 5 and 9 after tumour cell
inoculation, no major toxicity was observed. It is of interest to
mention that some signs of rough coat appeared in 100% of the
animals and that lethargy and closed eyes were observed for 25%
of the mice. Maximal weight loss was 4% observed at day 11, that
is, 2 days after the last administration of ICEU.
N-(4-iodophenyl)-N0-(2-chloroethyl)urea distributed to CT-
26 tumour in vivo and accumulated in CT-26 cells in vitro
To determine both the intratumoral uptake of the drug and its
biodistribution pattern, CT-26 tumour-bearing mice (mean
tumour volume¼176.9729.8mm
3) were treated i.p. with
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Figure 2 N-(4-iodophenyl)-N0-(2-chloroethyl)urea delayed the growth
of CT-26 colon carcinoma tumours in mice. Effect on tumour progression
of ICEU administered i.p. (13mgkg
 1) at days 1, 5 and 9 after tumour cell
inoculation (12 animals per group). Data correspond to average values of
tumoral volume with standard deviations indicated. Tumour growth
inhibition was statistically significant at days 9, 11 and 15.
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125I]ICEU at the MTD (13mgkg
 1; 74kBq). As early as 15min
postinjection, radioactivity was largely detected in the blood
circulation and in well-vascularised organs such as the lungs, liver
and kidneys, confirming the absorption of the drug (Figure 3A).
Tumour uptake of the radioactivity was also observed 15min after
administration with 1.370.1% of IDg
 1, reaching a stable
maximal value of 3.370.3% IDg
 1 at 3h until 24h postinjection.
Interestingly, radioactivity levels remained stable within the
tumour from 3h after injection while it was eliminated from
blood and others organs. We also observed an unexpected high
accumulation of radioactivity within the intestinal tract. To
determine whether this radioactive signal was coming from the
intestinal content or from the colonic tissue itself, we performed
radioactive counting of excised and washed colon tissue aliquots.
This additional study confirmed a high level of radioactivity
accumulation (reaching about 15% IDg
 1 from 30min to 12h
postadministration) within the intestinal tissue.
More than 75% of the dose of ICEU injected was eliminated
during the first 48h, with 53.3% of the dose being excreted in urine
(data not shown).
We have also evaluated the in vitro accumulation of [
125I]ICEU
in CT-26 cells after 24h of drug incubation at concentrations
ranging from 3 to 100mM. As illustrated in Figure 3B, [
125I]ICEU
uptake was dose dependent (R
2¼0.9926). Concerning the kinetics
of [
125I]ICEU uptake by the cells, uptake was rapid with
intracellular concentrations plateaued after 1h of incubation
(Figure 3C). Maximal [
125I]ICEU uptake was 5.8pmoles drugmg
 1
proteins (i.e. 9.2% of incubated dose) from 1 to 18h of incubation.
From 24 to 48h of incubation, [
125I]ICEU uptake fell to 5.1pmoles
drugmg
 1 proteins, but the decrease was not significant.
N-(4-iodophenyl)-N0-(2-chloroethyl)urea induced cell cycle
modifications in vitro and in vivo
In controls, 38.274.6% of CT-26 cells accumulated in the S phase,
thus reflecting a high proliferative activity. N-(4-iodophenyl)-N0-
(2-chloroethyl)urea treatment led to an increase in cell accumula-
tion in the G2 and sub-G1 phases (Figure 4A). Compared to
controls, escalating doses of ICEU induced a 1.2–4-fold increase of
the G2 population and a twofold increase of the sub-G1 content,
which is indicative of apoptosis. We studied the kinetics of this
response and observed that G2 and sub-G1 populations increased
exponentially with drug exposure. Nevertheless, both G2 and sub-
G1 populations were significantly increased as compared to
controls after 18h of drug exposure (Figure 4B).
Both control and ICEU-treated CT-26 tumours exhibited an
aneuploid cellular population in addition to the diploid population
(data not shown). Since G1 and sub-G1 aneuploid peaks were
difficult to distinguish from the G2 diploid peak, we only took into
account aneuploid G2 distribution. Figure 4C shows individual
percentages of accumulated aneuploid cells in G2 phase for both
control and ICEU-treated tumours at several time points during
therapy. At days 9 and 11, we observed a slightly higher aneuploid
G2 population in treated samples than in controls. This trend was
reversed from day 15 when tumour growth relapsed.
N-(4-iodophenyl)-N0-(2-chloroethyl)urea induced
alterations in b-tubulin migration on electrophoresis that
were detected in vitro but not in vivo
Alkylation of b-tubulin by CEUs has been shown to induce a
change in the b-tubulin migration behaviour. We looked for this
phenotype in cells incubated with labelled or unlabelled ICEU
(Figure 5A). CT-26 cells incubated with 100mM [
125I]ICEU for 24h
displayed a double immunoreactive band of b-tubulin (upper
panel, Figure 5A) that could be superimposed over the radioactive
ICEU protein (lower panel, Figure 5A); the ICEU-induced
alkylation of b-tubulin occurred in cultured CT-26 cells.
We then looked for the ‘b-tubulin double band phenotype’ on
western blots of ICEU-treated tumours at several stages, that is, (i)
days 9 and 11 that corresponded to a high tumour growth
inhibition, (ii) day 15 to a moderate tumour growth inhibition and
(iii) day 18 that corresponded to tumour relapse. The b-tubulin
alkylation phenotype could not be revealed on any samples
(Figure 5B). Nevertheless, the intensity of the b-tubulin band
appeared to be lower at days 9 and 11, which could be correlated to
a lower protein content (b-tubulin/b-actin ratio lower at these two
stages only, data not shown).
N-(4-iodophenyl)-N0-(2-chloroethyl)urea induced changes
in phospholipid membrane profile both in vitro and in vivo
Typical 1D
1H-NMR spectra of untreated and ICEU-treated CT-26
cells showed well-resolved resonances in the spectral region of
0.8–5.2ppm (Figure 6A): the predominant peaks arose from fatty
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Figure 3 N-(4-iodophenyl)-N0-(2-chloroethyl)urea distributed to tumour
cells in vitro and in vivo.( A)[
125I]ICEU distribution in CT-26 tumour graft
and tissues of mice. [
125I]ICEU (74kBq) was administered i.p. to mice
bearing CT-26 tumours. Data correspond to average uptake values of
[
125I]ICEU (in % IDg
 1), and bars illustrate s.e.m. (three mice per time
point). Radioactivity was retained within CT-26 tumours (3.3% IDg
 1) and
the colon (15% IDg
 1). (B)[
125I]ICEU uptake by CT-26 cells as a function
of drug concentration in the extracellular medium. Data correspond to
average uptake values with standard deviations indicated (experiments
were performed three times). [
125I]-ICEU uptake was dose dependent. (C)
Kinetics of [
125I]ICEU (30mM) uptake by CT-26 cells over a 48-h period.
Data correspond to average values with standard deviations indicated
(experiments were performed three times). Intracellular concentrations
reached the plateau after 1h of exposure.
ICEU as a microtubule disrupter
M Borel et al
1687
British Journal of Cancer (2007) 96(11), 1684–1691 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sacyl chains of lipids thus called mobile lipids (ML), with the
resonances of the methyl groups (CH3) and the methylene groups
(CH2) observed at 0.85–0.90 and 1.20–1.32ppm, respectively, the
doublet of lactate at 1.32 and 1.34ppm, lys at 1.71ppm, creatine at
3.03ppm, choline-containing compounds between 3.20 and
3.23ppm, and resonances from polyunsaturated fatty acids
(PUFA) at 5.20ppm. N-(4-iodophenyl)-N0-(2-chloroethyl)urea
treatment of CT26 cells led to changes in the signal intensity of
ML, PUFA and choline as a function of the period of exposure to
the drug (Figure 6A). For each incubation time, quantitative
analysis focused on the changes in ML/lys ratio respectively to
controls. As shown in Figure 6B, after 6h of incubation, the mean
ML/lys ratios were significantly higher in ICEU-treated cells than
in controls. It should be noted that ICEU-treated cells showed two
‘waves’ of ML/lys ratio increase. In one hand, a first ‘wave’
occurred between 3 and 6h (ML/lys¼10.9671.8 for ICEU-treated
cells vs 5.4671.8 for controls at the 6h time point). On the other
hand and after an intermediate plateau (6–18h), a second sharp
strong increase in ML/lys ratio was observed between 24 and 72h
time, reaching peak ML/lys ratio values of 59.978 for treated cells
vs 4.173 for controls at the 72h time point. To perform
assignments of the ML involved in this signal, 1D
31P spectra of
chloroform/methanol extracts were performed for both untreated
and ICEU-treated CT-26 cells. The results were then compared for
phospholipid metabolic changes. The phosphatidylethanolamine
to phosphatidylcholine ratio was significantly higher in ICEU-
treated cells (0.470.03) than controls (0.2570.02) (data not
shown).
The antitumoral activity of ICEU was also investigated, in vivo
by comparing treated tumour samples to controls at different time
points. As observed with the cell lines, resonances of methylene
groups from ML (1.20–1.32ppm) and PUFA (5.20ppm) of ICEU-
treated tumours increased in a time-dependent manner relatively
to lys, but the variation was weaker than in vitro (data not shown).
The most prominent changes in ICEU-treated tumour samples
were observed from signals acquired by
1H 2D COSY spectra
(Figure 6C) that distinguished the signals from choline (3.55ppm),
ethanolamine (3.15ppm), phosphocholine (3.62ppm), phospho-
ethanolamine (3.22ppm, both were designated as Plp1) and peaks
deriving from glycerophosphocholine (GPC) (3.68ppm) and
glycerophosphoethanolamine (GPE) (3.30ppm, both were named
as Plp2), known to be related to phospholipid biosynthesis and
breakdown in vivo, respectively. Figure 6C illustrates the typical
1H
2D COSY spectra of both the control and the treated tumours at
day 11 where a significant decrease of the metabolite signals could
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Figure 5 N-(4-iodophenyl)-N0-(2-chloroethyl)urea-induced alterations
in b-tubulin migration properties on SDS–PAGE gel; alterations were
detected in vitro but not in vivo.( A) Western blotting of b-tubulin from
extracts of CT-26 cells incubated with either DMSO or ICEU (unlabelled
or labelled with
125I): The alkylated b-tubulin migrated faster than the native
form (upper panel). This additional immunoreactive band could be
superimposed over the radioactive band, as shown by autoradiography
(lower panel). (B) Western blotting of b-tubulin from CT-26 tumour
extracts. Tumours were sampled at day 9 (samples T1 and T2), 11
(samples T3 and T4), -15 (samples T5 and T6) and -18 (sample T7) after
tumour cell inoculation. The additional immunoreactive band of b-tubulin
was not detected. Western blotting of ICEU-treated CT-26 cell extract
(noted þ) was added.
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sbe attributed to ICEU treatment, especially for peaks deriving from
Plp1 and Plp2. The changes in the relative peak areas for both Plp1
and Plp2 were analysed in treated tumours and compared to
controls. From day 9 (3h after the last treatment) to day 18 (9 days
after the last treatment), Plp2 signal decreased to very low levels
that were indistinguishable of the NMR background and did not
allow any quantitative analysis. For Plp1 signal, a significant
decrease in ICEU-treated tumours compared to controls was
observed at days 9 and 11 (Figure 6D). From day 15, there were no
significant differences in Plp 1 between ICEU-treated tumours and
controls.
DISCUSSION
The aim of this study was to investigate the antitumoral activity of
the new tubulin-interacting drug ICEU in the murine CT-26 colon
A B
C
D
0
0
∗
∗
∗
∗ ∗
0
1
2
3
4
5
6
7
9
P
l
p
1
 
(
r
e
l
a
t
i
v
e
 
p
e
a
k
 
a
r
e
a
)
*
*
ICEU-treated
Nontreated
M
L
 
/
 
L
y
s
 
r
a
t
i
o
70
60
50
40
30
20
10
Incubation time (h)
12 24 36 48 60 72
ICEU-treated 
tumours
Nontreated  
tumours
Days post tumour cell inoculation
18 15 12
72 h
48 h
24 h
18 h
6 h
3 h
5.0
6
5
4 3
2
1
5
4
2
1
4.4 4.2 4.0 3.8 3.6 3.4
4
.
5
4
.
0
3
.
5
F
1
 
[
p
p
m
]
4
.
5
4
.
0
3
.
5
F
1
 
[
p
p
m
]
F2 [ppm]
4.4 4.2 4.0 3.8 3.6 3.4
F2 [ppm]
4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
CH=CH
H2O
Total choline
Cr
Lys
CH3
CH2 lipids
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1H spectra changes in ICEU-treated cells.
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ICEU (30mM) for 3, 6, 18, 24, 48 and 72h. An increase in the signal intensity of both the mobile lipids and the polyunsaturated fatty acids, and a decrease in
the signal intensity of choline were observed. (B) Mobile lipids/lys ratio of both untreated and ICEU-treated cells as a function of drug incubation time. Data
correspond to average values with standard deviations (experiments were performed three times). In ICEU-treated cells, there was an increase in ML/lys
ratio that followed a ‘two-step kinetics’ pattern, that is at an early (3–6h after drug exposure) and then at a late stage (18–72h after drug exposure). (C)
Two-dimensional homonuclear correlated spectra COSY
1H spectra of both untreated (on the left) and ICEU-treated tumours (on the right-hand side) at
day 11 (CT-26-bearing mice received ICEU (13mgkg
 1) by i.p. route at days 1, 5 and 9 postimplantation). Cross peak assignments: (1) ethanolamine (2)
phosphoethanolamine (3) glycerophosphoethanolamine (4) choline (5) phosphocholine and (6) glycerophosphocholine. (D) Relative peak area of Plp1 of
both untreated and ICEU-treated tumours as a function of time during therapy. CT-26-bearing mice received ICEU (13mgkg
 1) by i.p. route at days 1, 5
and 9 postimplantation. Plp1 decreased significantly in ICEU-treated tumours at days 9 and 11 compared to controls.
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scarcinoma cell line at both the tissues and the cellular level. After
i.p. administration, ICEU was rapidly absorbed and largely
distributed in well-vascularised organs. Tumour uptake of
[
125I]ICEU reached a stable maximal value of 3.370.3% IDg
 1.
To our knowledge, this level of drug accumulation in the tumour
appears higher than that of 5-Fu accumulation, that is the current
‘gold standard’ drug for the first-line of colorectal cancer
treatment, reported in the same CT-26 tumour-bearing mice
model (Kamm et al, 2003). These data appeared to us of particular
interest since they supported our previous findings demonstrating
that 40mmolkg
 1 of ICEU administered i.p. was equipotent to
150mmolkg
 1 of 5-Fu administered i.v. to inhibit the growth of
CT-26 colon carcinoma tumours and increased lifespan of the
animals (Miot-Noirault et al, 2004). Interestingly, [
125I]ICEU was
retained within the tumour for a long time period while it was
eliminated from most organs 6h post administration. This
observation may act in favour of the in vivo antitumour activity
of ICEU since it appears from cell cycle kinetics analysis that a long
ICEU exposure time is necessary to induce a G2 blockage. It
seemed therefore essential to determine whether the long exposure
time necessary to observe a cytotoxicity was attributable to a
difficulty for the drug to reach the cells or was inherent to its
mechanism of action. Results from the cellular uptake study
evidenced a rapid dose-dependent uptake of ICEU by CT-26 cells.
This suggested a passive diffusion of the drug throughout the
biological membranes, as described previously for many other
lipophilic tubulin-interacting agents (Singer and Himes, 1992). To
that end, ICEU exhibits a calculated Log P of 2.8 (ChemDraw
software) and has been shown to interact easily with model lipid
bilayer membranes (Saint-Laurent et al, 2001). Considering the
cytotoxic activity of ICEU, it was recently demonstrated on B16
melanoma cells that the mechanism of action of ICEU was
mediated through its covalent binding to a glutamic acid residue at
position 198 of b-tubulin isoform 5 (Bouchon et al, 2005). In CT-26
cells, ICEU induced similar modifications of the b-tubulin
migration properties on SDS–PAGE. ICEU-modified-b-tubulin
and labelled ICEU proteins could be superimposed, suggesting that
the additional b-tubulin band results from the irreversible binding
of ICEU to the protein. We also looked for the ‘b-tubulin double
band phenotype’ on western blots of ICEU-treated tumours at
several stages during and after the treatment, that is, days 9, 11, 15
and 18 of the protocol. This sampling time window was chosen at
several stages of the CT-26 tumour response to ICEU treatment on
the basis of our previously published results that have shown with
the same protocol, (i) a high inhibition of the tumour growth at the
stages day 9 and day 11, (ii) a moderate growth inhibition at day 15
and (iii) a relapse of the tumours at day 18 (Miot-Noirault et al,
2004). No b-tubulin alkylation phenotype could be observed, even
for the stages day 9 and day 11, which corresponded to a tumour
growth inhibition of 59.8 and 75.4%, respectively. Nevertheless,
at these two stages, some ICEU-treated tumours showed a low
b-tubulin/b-actin ratio, thus suggesting a lower content of native
b-tubulin. We were unable to detect in vivo the additional band
corresponding to the alkylated tubulin: this was a typical case of
lack of correlation between a drug’s cellular effects and its in vivo
antitumour effect. That phenomenon is not unique, as it has been
already reported for other antimicrotubule agents by Schimming
et al (1999). We hypothesise that cells with alkylated b-tubulin
might be eliminated quickly in vivo via phagocytosis and/or
ubiquitin proteasome degradation pathways, as described pre-
viously (Krysko et al, 2006; Liu et al, 2006; Wang et al, 2006).
Likewise, the tumoricidal concentration of ICEU necessary to kill
cells should be higher as compared to in vitro when one considers
the interrelated influence of physiological parameters such as
perfusion, necrosis, cell density and interstitial pressure that may
affect the diffusion of the drug into the tumoral tissues and the
neoplastic cells. This difference in vitro vs in vivo was also
observed with data obtained from cell cycle experiment analysis:
In vitro, a percentage (around 40% of total cell number) were
blocked in G2 phase while in vivo only a slight increase in the G2
tetraploid phase could be observed at days 9 and 11, which are
both corresponding to the significant tumour growth inhibition
observed. After day 15, the aneuploid G2 population was lower in
treated samples than in controls. As previously hypothesised, the
tumour cells that exhibited an aneuploid status (due to a
block in mitosis by ICEU treatment) probably underwent
apoptosis and were quickly eliminated via immune system
(Weaver and Cleveland, 2005). We have monitored the ‘death
programme’ (i.e. apoptosis or cell necrosis) of CT-26 cells cultured
and grafted to mice, when exposed to ICEU. Toward that end,
1H-
NMR spectrometric analysis was used as a quantitative method for
the noninvasive evaluation of biochemical processes involved in
cell proliferation and growth arrest (Valonen et al, 2005).
Moreover, we performed the
1H-NMR analysis at the magic angle,
which is called
1H-HRMAS NMR spectroscopy, that provides an
improved spectral resolution and allows a direct analysis of
‘semisolid’ samples (cell pellet or tumour tissue) without the need
of tissue extraction procedures. Since
1H-HRMAS NMR analysis
do not compromise the biochemical and structural integrity of
cells and tissues, it is considered that the lipid changes detected by
a such methodology originate from the biochemically active pools
of the sample (Weybright et al, 1998). From our results, we may
hypothesise that cells blocked in G2 phase underwent apoptosis, as
confirmed by a sharp increase in CH2 of ML resonances in NMR
spectra: In vitro, when CT-26 cells were exposed to ICEU, a sharp
increase in CH2 of ML resonances was observed. This lipid signal
arose from fatty acyl chains in triglycerides arranged in micro-
domains embedded in the plasma membrane bilayer (Blankenberg
et al, 1996, 1997). Interestingly, in ICEU-treated CT-26 cells, ML
were generated at an early stage (3–6h) as well as a late stage (18–
72h) after drug exposure. The early lipid signal changes probably
arose from the interactions described recently and occurring
between ICEU and the lipid bilayer membranes (Saint-Laurent
et al, 2001). The late lipid signal changes (observed after 18h) may
be considered as markers of the apoptotic cascade, therefore
reflecting plasma membrane reorganisation and phosphatidyl-
serine externalisation (Blankenberg et al, 1996, 1997; Bezabeh et al,
2001; Brisdelli et al, 2003). Moreover, after the latter stage, there
was a decrease in choline that indicates cell death (Blankenberg
et al, 1996, 1997). In ICEU-treated tumours, there was a decrease in
the Plp1 membrane precursors detected (i.e. phosphocholine and
phosphoethanolamine), suggesting that ICEU causes a reduction in
cell membrane turnover and cell proliferation, thus leading to the
decrease of Plp 2 membrane degradation products (GPC and GPE)
simultaneously to tumour growth inhibition (Lindskog et al, 2004;
Valonen et al, 2005). When tumour proliferation relapsed (as
confirmed by tumour volume assessment), there were no
differences in phosphoethanolamine and phosphocholine levels
between treated and control tumours. Despite tumour growth
recovery, Plp 2 signal remained at low levels. This may be
attributed to a certain level of necrosis in the tumour as a
consequence of an antiangiogenic activity as commonly described
for anti-tubulin agents (McPhail et al, 2005). It is noteworthy that
ICEU has been described recently to block angiogenesis (Petitclerc
et al, 2004).
In summary, ICEU is readily absorbed and rapidly biodistrib-
uted to CT-26 carcinoma tumour tissues and cells, inducing
b-tubulin alkylation that leads to a G2 phase arrest, inhibition of
cell proliferation and a reduction in cell membrane turnover and
proliferation, events that all together contributed to tumour
growth inhibition. Moreover, the treatment appeared ‘well-
tolerated’ with no major side effects being observed. Unexpectedly,
a high accumulation of radioactivity was observed within the
intestinal tract, which was attributed to colon tissue structure. To
our opinion, the accumulation of [
125I]ICEU within colon tissues
could be an important feature for further investigations with a
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sview of developing efficacious treatments for colorectal cancers. In
the light of these results, research is in progress to assess both the
distribution and efficacy of ICEU in the CT-26 tumour, being
orthotopically implanted in mice.
REFERENCES
Bechard P, Lacroix J, Poyet P, C-Gaudreault R (1994) Synthesis and
cytotoxic activity of new alkyl[3-(2-chloroethyl)ureido]benzene deriva-
tives. Eur J Med Chem 29: 963–966
Bezabeh T, Mowat MRA, Jarolim L, Greenberg AH, Smith ICP (2001)
Detection of drug-induced apoptosis and necrosis in human cervical
carcinoma cells using
1H NMR spectroscopy. Cell Death Differ 8:
219–224
Blankenberg FG, Katsikis PD, Storrd RW, Beaulieu C, Spielman D, Chen JY,
Naumovski L, Tait JF (1997) Quantitative analysis of apoptotic cell
death using proton nuclear magnetic resonance spectroscopy. Blood 89:
3778–3786
Blankenberg FG, Storrs RW, Naumovski L, Goralski T, Spielman D (1996)
Detection of apoptotic cell death by proton nuclear magnetic resonance
spectroscopy. Blood 87: 1951–1956
Bouchon B, Chambon C, Mounetou E, Papon J, Miot-Noirault E,
Gaudreault RC, Madelmont JC, Degoul F (2005) Alkylation of b-tubulin
on Glu 198 by a microtubule disrupter. Mol Pharmacol 68: 1415–1422
Bradford MM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 72: 248–254
Brisdelli F, Iorio E, Knijn A, Ferretti A, Marcheggiani D, Lenti L, Strom R,
Podo F, Bozzi A (2003) Two-step formation of
1H NMR visible mobile
lipids during apoptosis of paclitaxel-treated K562 cells. Biochem
Pharmacol 65: 1271–1280
Cabral F (2001) Factors determining cellular mechanisms of resistance to
antimitotic drugs. Drug Resist Update 4: 3–8
Drukman S, Kavallaris M (2002) Microtubule alterations and resistance to
tubulin-binding agents. Int J Oncol 21: 621–628
Gaudreault RC, Lacroix J, Page M, Joly LP (1988) Synthesis and in vitro
assay of 1-aryl 3-(2-chloroethyl) ureas as potential anticancer agents.
J Pharm Sci 77: 185–188
Kamm YJL, Peters GJ, Hull WE, Punt CJA, Heerschap A (2003) Correlation
between 5-fluorouracil metabolism and treatment response in two
variants of C26 murine colon carcinoma. Br J Cancer 89: 754–762
Krysko DV, D’Herde K, Vandenabeele P (2006) Clearance of apoptotic
and necrotic cells and its immunological consequences. Apoptosis 11:
1709–1726
Labarre P, Papon J, Moreau MF, Moins N, Veyre A, Madelmont JC (1999)
Evaluation in mice of some iodinated melanoma imaging agents using
cryosectioning and multiwire proportional counting. Eur J Nucl Med 26:
494–498
Lacroix J, C-Gaudreault R, Page M, Joly LP (1988) In vitro and in vivo
activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic
agents. Anticancer Res 8: 595–598
Legault J, Gaulin JF, Mounetou E, Bolduc S, Lacroix J, Poyet P, Gaudreault
RC (2000) Microtubule disruption induced in vivo by alkylation of
b-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating
agents. Cancer Res 60: 985–992
Lindskog M, Spenger C, Jarvet J, Graslund A, Kogner P (2004) Predicting
resistance or response to chemotherapy by proton magnetic resonance
spectroscopy in neuroblastoma. J Natl Cancer Inst 96: 1457–1466
Liu G, Wu C, Wu Y, Zhao Y (2006) Phagocytosis of apoptotic cells and
immune regulation. Scand J Immunol 64: 1–9
McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR,
Robinson SP (2005) Tumor dose response to the vascular disrupting
agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic
resonance spectroscopy. Clin Cancer Res 11: 3705–3713
Miot-Noirault E, Legault J, Cachin F, Mounetou E, Degoul F, Gaudreault
RC, Moins N, Madelmont JC (2004) Antineoplastic potency of
arylchloroethylurea derivatives in murine colon carcinoma. Invest New
Drugs 22: 369–378
Mounetou E, Legault J, Lacroix J, Gaudreault RC (2001) Antimitotic
antitumour agents: synthesis, structure–activity relationships and
biological characterization of N-aryl-N-(2-chloroethyl)ureas as new
selective alkylating agents. J Med Chem 44: 694–702
Mounetou E, Legault J, Lacroix J, Gaudreault RC (2003) A new generation
of N-aryl-N_-(1-alkyl-2-chloroethyl)ureas as microtubule disrupters:
synthesis, antiproliferative activity and beta-tubulin alkylation kinetics.
J Med Chem 46: 5055–5063
Petitclerc E, Deschesnes RG, Cote MF, Marquis C, Janvier R, Lacroix J,
Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, Gaudreault RC
(2004) Antiangiogenic and antitumoural activity of phenyl-3-(2-chlor-
oethyl)ureas: a class of soft alkylating agents disrupting microtubules
that are unaffected by cell adhesion-mediated drug resistance. Cancer Res
64: 4654–4663
Saint-Laurent A, Boudreau N, Lariviere D, Legault J, Gaudreault RC, Auger
M (2001) Membrane interactions of a new class of anticancer agents
derived from arylchloroethylurea: a FTIR spectroscopic study. Chem
Phys Lipids 111: 163–175
Sapan CV, Lundblad RL, Price NC (1999) Colorimetric protein assay
techniques. Biotechnol Appl Biochem 29: 99–108
Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L (1999) Lack
of correlation between mitotic arrest or apoptosis and antitumor effect of
docetaxel. Cancer Chemother Pharmacol 43: 165–172
Singer WD, Himes RH (1992) Cellular uptake and tubulin binding
properties of four Vinca alkaloids. Biochem Pharmacol 43: 545–551
Sitter B, Sonnewald U, Spraul M, Fjo ¨sne HE, Gribbestad IS (2002) High-
resolution magic angle spinning MRS of breast cancer tissue. NMR
Biomed 15: 327–337
Valonen PK, Griffin JL, Lehtimaki KK, Liimatainen T, Nicholson JK, Grohn
OHJ, Kauppinen RA (2005) High-resolution magic-angle-spinning
1H
NMR spectroscopy reveals different responses in choline-containing
metabolites upon gene therapy-induced programmed cell death in rat
brain glioma. NMR Biomed 18: 252–259
Wang Y, Tian G, Cowan NJ, Cabral F (2006) Mutations affecting b-tubulin
folding and degradation. J Biol Chem 281: 13628–13635
Weaver BA, Cleveland DW (2005) Decoding the links between mitosis,
cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell
death. Cancer Cell 8: 7–12
Weybright P, Millis K, Campbell N, Cory DG, Singer S (1998) Gradient,
high-resolution, magic angle spinning
1H nuclear magnetic resonance
spectroscopy of intact cells. Magn Reson Med 39: 337–345
Wilson L, Jordan MA (2004) New microtubule/tubulin-targeted anticancer
drugs and novel chemotherapeutic strategies. J Chemother 16(Suppl 4):
83–85
Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J,
Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J
(1998) United Kingdom Coordinating Committee on Cancer Research
(UKCCCR) guidelines for the welfare of animals in experimental
neoplasia (2nd ed.). Br J Cancer 77: 1–10
ICEU as a microtubule disrupter
M Borel et al
1691
British Journal of Cancer (2007) 96(11), 1684–1691 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s